EW:NYSEEdwards Lifesciences Corporation Analysis

Edwards Lifesciences is trading at $86.47, comfortably above its 20‑day SMA of 83.01 and the 50‑day SMA of 81.74, with the 200‑day SMA at 81.50, confirming a sustained bullish trend. The RSI of 61.6 and a bullish MACD histogram of 0.53 further signal upward momentum, while volume is on an increasing trajectory. The stock is holding above the technical support of $76.49 and approaching a resistance near $88.28, suggesting limited near‑term upside before a potential pull‑back.
Fundamentally, EW delivers robust 16.7% revenue growth, 78% gross margin, and a healthy operating margin of 31%, backed by $3.67 B of cash and modest debt of $0.70 B. However, the current price implies a forward P/E of 25.7 versus an industry average of 27.6, while the DCF‑derived fair value of $46.53 flags significant overvaluation of roughly 12‑13%. Analysts remain bullish, with a median target of $99.5 and a “buy” consensus, and recent news highlights expanding aortic‑valve franchise and a new CFO appointment, offset by concerns over conservative accounting that may soften earnings.